000			02382 a2200757 4500
005			20250513234753.0
264		0	_c20010531
008			200105s 0 0 eng d
022			_a0022-1899
024	7		_a10.1086/319863 _2doi
040			_aNLM _beng _cNLM
100	1		_aBelshe, R B
245	0	0	_aSafety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. _h[electronic resource]
260			_bThe Journal of infectious diseases _cMay 2001
300			_a1343-52 p. _bdigital
500			_aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAIDS Vaccines _xgenetics
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAvipoxvirus _ximmunology
650	0	4	_aCD8-Positive T-Lymphocytes _ximmunology
650	0	4	_aDouble-Blind Method
650	0	4	_aFemale
650	0	4	_aGenetic Vectors
650	0	4	_aHIV Envelope Protein gp120 _xgenetics
650	0	4	_aHIV Infections _xprevention & control
650	0	4	_aHIV Protease _xgenetics
650	0	4	_aHIV-1 _ximmunology
650	0	4	_aHumans
650	0	4	_aImmunization Schedule
650	0	4	_aImmunization, Secondary
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aRisk Factors
650	0	4	_aSafety
650	0	4	_aT-Lymphocytes, Cytotoxic _ximmunology
650	0	4	_aVaccines, Attenuated
650	0	4	_aVaccines, Synthetic
700	1		_aStevens, C
700	1		_aGorse, G J
700	1		_aBuchbinder, S
700	1		_aWeinhold, K
700	1		_aSheppard, H
700	1		_aStablein, D
700	1		_aSelf, S
700	1		_aMcNamara, J
700	1		_aFrey, S
700	1		_aFlores, J
700	1		_aExcler, J L
700	1		_aKlein, M
700	1		_aHabib, R E
700	1		_aDuliege, A M
700	1		_aHarro, C
700	1		_aCorey, L
700	1		_aKeefer, M
700	1		_aMulligan, M
700	1		_aWright, P
700	1		_aCelum, C
700	1		_aJudson, F
700	1		_aMayer, K
700	1		_aMcKirnan, D
700	1		_aMarmor, M
700	1		_aWoody, G
773	0		_tThe Journal of infectious diseases _gvol. 183 _gno. 9 _gp. 1343-52
856	4	0	_uhttps://doi.org/10.1086/319863 _zAvailable from publisher's website
999			_c11229840 _d11229840